SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid discussions about its financial performance and the ongoing release of Epstein-related documents. The community is expressing concerns about the company's future and the potential impact of these external factors, including political opinions and a mix of reactions, from staunch support to harsh criticism. Speculation is also circulating regarding potential market manipulation and the stock's long-term viability.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it dips below $100K, sparking discussions about potential support levels and the possibility of a larger correction. The crypto community is debating whether this is a buying opportunity or the start of a bear market, with some pointing to ETF flows and long-term holder behavior.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid a recent announcement of a $2.35 billion senior secured notes offering, leading to community debate around the company's debt strategy and its potential impact on growth. Community members are weighing the implications of this financial move against the backdrop of the AI sector's volatility, discussing whether this is a buying opportunity or a sign of deeper issues. Despite differing opinions, the company's existing contracts and long-term potential in the AI data center space remain central talking points.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a decision on its Alzheimer's treatment from the European Medicines Agency, with a hearing completed recently. Community discussions range from potential approval and short squeeze scenarios to concerns about data integrity and potential insider trading, fueled by commentary from controversial figures. The stock exhibits high volatility amidst speculation about the drug's prospects and impact on the broader Alzheimer's treatment landscape.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to lowered FY2025 revenue guidance, sparking concerns about short-term performance, while the community debates management and potential reverse splits. Despite the reduced outlook, long-term growth prospects related to defense and maritime contracts, along with analyst 'Strong Buy' ratings, are still being discussed, with some viewing the dip as a buying opportunity.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending downwards as investors express concerns about decreased revenue and profit, despite overall year-to-date growth. The community is debating whether recent facility upgrades and reliance on Dell will support future expansion and profitability, especially given lower numbers in recent earnings. Contrarian investors are hopeful for a bounce, citing a recent capital raise, while others express disappointment and question the company's communication strategy.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending amid speculation of a potential acquisition, with community members discussing rumors of a bidding war involving major pharmaceutical companies. The positive Phase 2 clinical data for their influenza candidate CD388 and a recent $339M BARDA award have increased optimism around the stock. Investors are closely watching for further developments, including potential price target updates and signals of a buyout.

Applied Materials, Inc. provides manufacturing equipment, services and software to the semiconductor, display and related industries. It operates through the following segments: Semiconductor Systems, Applied Global Services, and Display. The Semiconductor Systems segment includes semiconductor capital equipment for etch, rapid thermal processing, deposition, chemical mechanical planarization, metrology and inspection, wafer packaging, and ion implantation. The Applied Global Services segment provides solutions to optimize equipment, performance, and productivity. The Display segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, equipment upgrades, and other display technologies for TVs, monitors, laptops, personal computers, smart phones, and other consumer-oriented devices. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending due to a mixed earnings report and weaker-than-expected guidance, sparking debate about its future growth prospects, particularly in China. The community is focused on whether the recent drop presents a buying opportunity or if it signals deeper challenges for the semiconductor equipment supplier. Discussions include the impact of potential tariffs and competition from other companies in the sector.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is trending due to recent FDA approval of their leukemia drug, KOMZIFTI, ahead of schedule, leading to community excitement around its potential market impact and improved safety profile compared to competitors. The community is actively discussing the implications of the approval, including potential milestone payments and the drug's advantages in dosing and safety, while also considering its competitive positioning against similar treatments. Despite some volatility and profit-taking, the approval is seen as a positive catalyst for the company's growth and potential acquisition.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss its potential for government backing and key developments from the latest earnings report. The community is focused on the CEO's trip to Washington D.C. and anticipation surrounding NOAA approval, with some highlighting the company's role in securing defense minerals amid geopolitical tensions.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, 89BIO, McKesson, AbbVie, and Teva Pharmaceutical Industries are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised 

Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer

Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer. 

Shares of Viking Therapeutics rose 3.4% to $26.25 on Monday and extended gains after hours,&nbsp;with a Wall Street research firm suggesting the biopharma is benefiting from Pfizer’s buyout offer for Metsera as it looks to bolster its obesity drug pipeline.BTIG reiterated a ‘Buy’ rating and $125 price target on&nbsp;Viking’s stock, saying the transaction sharpens&nbsp;the company’s&nbsp;clinical updates and strategic optionality while bolstering sentiment ahead of key readouts. The commentary followed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/89bio-stock-surges-roche-3-5b-buyout-wall-street-analyst-cautious/chDdNVaR3br">Roche’s acquisition of 89bio</a>, signaling increased deal activity in the biotech space.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> surged to an all-time high Monday, marking their biggest one-day gain ever.&nbsp;As part of the deal, Pfizer will pay Metsera $47.50 in cash per share, giving the company an enterprise value of $4.9 billion. If three clinical milestones are achieved, additional payments of $22.50 per Metsera share will be made, bringing the total value of the deal to as much as $7.3 billion. The deal is expected to close in the fourth quarter of 2025, pending approvals.Metsera, a clinical-stage biotech developing therapies for obesity and cardiometabolic diseases, will add four differentiated programs to Pfizer's pipeline. The assets include weekly and monthly injectable GLP-1 receptor agonists, two orally delivered GLP-1 candidates, and MET-233i, a monthly injectable amylin analog. The company previously discontinued its own obesity candidate Danuglipron.Viking was also in the spotlight, with Daniel Newman, CEO of Futurum Equities,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/1970178447411683535">posting on X</a> that Viking’s valuation “just got a massive shot in the arm with the Pfizer deal to buy Metsera,” describing Metsera’s GLP-1 program as “a far less exciting GLP” and arguing that Viking is “worth far more than $7.2 billion.”On Stocktwits, retail sentiment was ‘extremely bullish’ for both Pfizer and Metsera amid ‘extremely high’ message volume, while Viking drew ‘bullish’ sentiment alongside ‘high’ activity.One bullish user said Viking management had likely rejected lowball offers from large pharma, leaving rivals to acquire ‘inferior pipelines.<stembedurl>https://stocktwits.com/deerhtide/message/629602680</stembedurl>Another pointed to debate over whether Viking should pursue a buyout or go-it-alone strategy, adding that CEO Brian Lian’s stake of more than two million shares aligns him with investors. The user disclosed holding 83,000 shares, calling the position conviction-driven.<stembedurl>https://stocktwits.com/SauceMan912/message/629604221</stembedurl>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> is down 4.5%, Metsera’s shares have more than doubled, and&nbsp;<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics’ stock</a> has fallen 34.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Equity

Wolfe Research’s Andy Chen cut his rating on 89bio to 'Peer Perform' from 'Outperform'&nbsp;and did not assign a price target after the biotech firm agreed to a $3.5 billion takeover by Roche.&nbsp;<a href="https://stocktwits.com/symbol/ETNB">89bio’s stock</a> surged 85% on Thursday to end at $14.96, its best day on record and the highest level in about a year and a half, before easing 0.03% in after-hours trading.<a href="https://stocktwits.com/news-articles/equity/markets/why-did-89bio-stock-nearly-double-in-value/chDcHJIR3bc">Roche is paying $14.50 a share in cash for 89bio</a>, about 79% above where the stock closed on Wednesday. Investors will also get the chance at another $6 a share in cash if certain milestones are met, though those rights won’t be tradable.&nbsp;On a fully diluted basis, the transaction values 89bio at up to $3.5 billion. An affiliate of Roche will launch a tender offer to acquire all outstanding shares, with closing expected in the fourth quarter, subject to customary conditions. Until then, 89bio will continue to operate independently before joining Roche’s pharmaceuticals division.The acquisition brings Roche 89bio’s late-stage drug candidate Pegozafermin, which is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive liver disease characterized by fat accumulation leading to inflammation and tissue damage.According to Koyfin, 89bio’s stock has an average 12-month analyst price target of $30.8, with estimates ranging from $12 to $55. The company is covered by 10 analysts, with seven ‘Buy’ ratings, two ‘Hold,’ and no ‘Sell.’ The average rating is ‘Buy.’&nbsp;On Stocktwits, retail sentiment around 89bio was described as 'extremely bullish' with 'extremely high' message volume, while sentiment on Roche was 'bullish' with 'normal' activity.One user noted that Roche’s purchase of 89bio could be part of a broader strategic shopping spree, adding that Sarepta Therapeutics might be next, given the two companies’ long-standing partnership. The user also suggested that Amgen or Pfizer could make competing offers and stated that they planned to hold their position and watch developments.<stembedurl>https://stocktwits.com/GaborPiscis/message/629152949</stembedurl>Another user wondered whether Tempest Therapeutics might be a possible target for Roche following the 89bio deal.<stembedurl>https://stocktwits.com/Fandango23/message/629193287</stembedurl>While 89bio’s stock has risen 91% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s stock</a> has climbed 21% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

While 89bio’s stock (ETNB) has risen 91% so far in 2025, Roche’s stock (RHHBY) has climbed 21% over the same period. (Photo credit: Getty Images)

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious 

The acquisition brings Roche rights to Pegozafermin, now in late-stage trials for liver disease MASH.

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline 

Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline. 

Shares of 89bio, Inc. (ETNB) jumped 86% in the pre-market session on Thursday after the company said that it has entered into a merger agreement to be acquired by Roche (RHHBY) for up to $3.5 billion on a fully diluted basis.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche">stated</a> that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday. 89bio shareholders will also receive a non-tradeable contingent value right to receive up to an aggregate of $6 per share in cash receivable upon the achievement of certain milestones.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ETNB">ETNB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_7_35_04_AM_png_e0cb1a5888.webp" alt="ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="573" height="59"><figcaption>ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user urged investors to buy the stock now.<stembedurl>https://stocktwits.com/FlyingChemist01/message/629085636</stembedurl>Another opined that the buyout represents a broader trend in which good biopharmaceutical firms are being acquired.<stembedurl>https://stocktwits.com/John62/message/629085287</stembedurl>Under the deal, an affiliate of Roche will commence a tender offer to acquire all of 89bio’s outstanding shares.The closing of the transaction is expected to occur in the fourth quarter, subject to the fulfillment of all closing conditions. Until then, 89bio will operate as a separate and independent company. After the closing of the deal, 89bio will join the Roche group as part of its pharmaceuticals division.The deal includes 89bio’s Pegozafermin, currently in late-stage trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive disease characterized by the accumulation of fat in the liver, leading to inflammation and tissue damage.ETNB stock is up 3% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-surge-after-fed-signals-more-rate-cuts-in-2025/chDcuaaR3GC">Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did 89bio Stock Nearly Double In Value Today?

89bio announced that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday.

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52

Companies developing therapies for metabolic steatohepatitis (MASH) saw strong gains even as Novo Nordisk (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) announced that its GLP-1 drug, semaglutide, demonstrated “superior improvement” in treating the liver disease in its phase 3 ESSENCE trial.&nbsp;Shares of Madrigal Pharmaceuticals (<a class="mention" data-mention="$MDGL" data-symbol-id="MDGL" href="https://stocktwits.com/symbol/MDGL" target="_blank">$MDGL</a>), which received FDA approval earlier this year for its MASH drug, Rezdiffra, rose by 18% following the announcement, with 89Bio (<a class="mention" data-mention="$ETNB" data-symbol-id="ETNB" href="https://stocktwits.com/symbol/ETNB" target="_blank">$ETNB</a>) and Akero Therapeutics (<a class="mention" data-mention="$AKRO" data-symbol-id="AKRO" href="https://stocktwits.com/symbol/AKRO" target="_blank">$AKRO</a>) seeing gains of 15% and 4%, respectively.Novo Nordisk’s ESSENCE trial, a 240-week, double-blind study involving 1,200 adults with MASH and moderate to advanced liver fibrosis, achieved its primary endpoints.&nbsp;After 72 weeks, patients receiving a weekly dose of 2.4 mg semaglutide showed significant liver fibrosis improvement without worsening steatohepatitis, as well as steatohepatitis resolution with no worsening of liver fibrosis, compared to those on placebo.&nbsp;"We are very pleased about the ESSENCE clinical trial results and the potential of semaglutide to help people living with MASH. Among people with overweight or obesity, one in three live with MASH. This has a serious impact on their health and represents a significant unmet need," said Martin Holst Lange, Novo’s executive vice president.The FDA has yet to approve GLP-1 drugs for MASH, though several early trials have shown promise in reversing the disease’s initial stages.&nbsp;In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.&nbsp;On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.&nbsp;Canaccord boosted its target on Madrigal to $394, citing confidence in continued revenue growth, while UBS increased its target to $441, highlighting an “underappreciated opportunity” in MASH and potential validation from Novo’s findings.<figure class="image"><a href="https://stocktwits.com/symbol/MDGL"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MDGL_sentiment_and_message_volume_Nov_1_69ab9366a3.png" alt="MDGL sentiment and message volume Nov 1.png" width="1314" height="320"></a><figcaption>MDGL sentiment and message volume Nov 1 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for MDGL remained ‘extremely bullish’ as of Friday afternoon amid a spike in message volume, with many fixated on Thursday’s strong results.<stembedurl>https://stocktwits.com/GXD_Texas/message/590911195</stembedurl>Some were also penciling in the next resistance levels for the stock that broke out over $300 this week.<stembedurl>https://stocktwits.com/TheProphetOfProfit/message/590910821</stembedurl>Madrigal’s stock has surged over 33% year-to-date, significantly outperforming broader market benchmarks.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/epix-stock-falls-after-drug-trial-fails/cJEYt4ERBm">Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade</a>

On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat

In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

89bio Inc

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

ETNB
89bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ETNB News

ETNB89bio Inc